Evidence map›Paper›PMID 37007766›Full record

ArticleFrontiers in medicine2023

Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome.

Simon Bossart, S Morteza Seyed Jafari, Kristine Heidemeyer, Kexiang Yan, Laurence Feldmeyer, Luca Borradori, Nikhil Yawalkar

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Simon BossartDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
S Morteza Seyed JafariDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Kristine HeidemeyerDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Kexiang YanDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Laurence FeldmeyerDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Luca BorradoriDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nikhil YawalkarDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
University Hospital of Bern · CHFudan University · CNUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.

Indexed as

autoinflammatory disordersCanakinumabimmunohistochemicalneutrophilic inflammationSchnitzler syndrome

Identifiers

PMID37007766
PMCPMC10050468
OpenAlexW4324373895

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read19
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.